The U.S. Food and Drug Administration reissued a decision first made by the agency in October that a shortage of the diabetes ...

Approved in 2022 for type 2 diabetes and in 2023 for chronic weight management along with diet and exercise, tirzepatide is ...

NFL News: Steelers get intriguing update on backup QB Justin Fields after Russell Wilson's subpar performance ...

The FDA said Thursday it’s standing by its earlier decision that the shortage of tirzepatide — the active ingredient in Eli ...

The US Food and Drug Administration approved a new indication for Eli Lilly’s formulation of tirzepatide to treat moderate to ...

The decision will largely prevent compounding pharmacies from making and selling compounded versions of the drug in the next ...

On Dec. 20, the FDA announced that the agency has approved Eli Lilly's Zepbound (tirzepatide) to treat moderate to severe ...

The nod, just months after topline results from SURMOUNT-OSA came out, makes it the first drug approved for this indication.

Tirzepatide, the active ingredient in both Mounjaro for type 2 diabetes and Zepbound for weight loss, was in short supply for ...

The approval was based on the results of the SURMOUNT-OSA trial, which found patients had fewer breathing disruptions.

A new evidence review says that coffee and tea consumption are linked to a lower risk of cancers of the mouth, throat, and ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 502.93% and ...